Emory University School of Medicine

Summary

Emory University School of Medicine is a medical facility located in Atlanta, Georgia. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Sickle Cell Disease, Fabry Disease and other specialties. Emory University School of Medicine is involved with conducting 295 clinical trials across 491 conditions. There are 25 research doctors associated with this hospital, such as Olatunji Alese, Melinda L. Yushak, Jane L Meisel, and Muna Qayed, MD, MS.

Top PIs

Clinical Trials running at Emory University School of Medicine

Sickle Cell Disease

Prader-Willi Syndrome

Bladder Cancer

Cardiovascular Disease

Overeating

Kidney Disorders

Spinal Cord Injury

Fabry Disease

Heart Disease

Kidney Disease

Etavopivat

for Sickle Cell Anemia

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Recruiting

2 awards

Phase 3

FTX-6058

for Sickle Cell Disease

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.

Recruiting

1 award

Phase 1

Curative Therapies

for Sickle Cell Disease

Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.

Recruiting

1 award

N/A

4 criteria